Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Microsatellite Instability 1Melanoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 12Gemcitabine 9Cetuximab 7Psychiatric Rehabilitation 6Paclitaxel 6Magnetic Resonance Spectroscopy 6Fluorouracil 6Early Intervention, Educational 6Cisplatin 6cediranib 5Leucovorin 5Carboplatin 5sargramostim 4Standard of Care 4Oxaliplatin 4Methods 4Erlotinib Hydrochloride 4Docetaxel 4Cyclophosphamide 4selpercatinib 3aldesleukin 3adagrasib 3Trastuzumab 3Therapeutics 3Pemetrexed 3Nivolumab 3Irinotecan 3Fluorodeoxyglucose F18 3Bortezomib 3Bevacizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × ALT-803 × Thoracic × Clear all
NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡